Aminoguanidine – (79-17-4)

Pimagedine, also known as aminoguanidine, is an investigational drug that was under development for the treatment of diabetic nephropathy. It functions as an inhibitor of diamine oxidase and nitric oxide synthase, reducing levels of advanced glycation end-products (AGEs) by interacting with reactive species like 3-deoxyglucosone, glyoxal, and methylglyoxal, converting them into less reactive heterocycles.

Pimagedine was initially developed by Alteon (now Synvista Therapeutics Inc.) in collaboration with Marion Merrell Dow Inc. and later Genentech. However, clinical trials were discontinued due to safety concerns and lack of efficacy, particularly in Phase III trials for non-insulin-dependent diabetes patients with overt nephropathy and end-stage renal disease.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Pimagedine
https://www.medchemexpress.com/aminoguanidine.html
https://www.medkoo.com/products/34814
https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/aminoguanidine